Expression Analysis (EA), a Quintiles company, announced that it is co-sponsoring a grant programme that provides scientists with leading-edge products and services to advance genomics research.
In the sixth year of the grant programme, EA and co-sponsor, Illumina, will award two fully funded oncology research grants. Each grant will enable winners to investigate genomic data locked within Formalin-Fixed, Paraffin Embedded (FFPE) tumour samples – focusing on a largely untapped data pool in an effort to enhance researchers’ understanding of cancer biology.
“Our grant programme offers motivation, encouragement and resources to researchers who share our commitment to identify genetic factors that influence health and disease,” said Steve McPhail, president of EA. “The grants serve to energise the quest for further advances in detecting biologically important genetic variations in oncology.”
“We are once again pleased to join EA in providing grants to researchers to uncover novel genetic insights important to human health and the diagnosis and treatment of disease,” said Tina Nova, senior vice president and general manager, oncology for Illumina.
The 2014 Oncology Research Grant Program is focused on helping oncology researchers unlock the potential within FFPE tumour samples through the assessment of methylation status using the Illumina Infinium HumanMethylation450 BeadChip and next-generation sequencing based differential expression using the Illumina TruSeq RNA Access Library Prep Kit.
Grant applications will be reviewed and scored by technical experts at EA and Illumina. Applications for the grant are due by September 26, 2014. For more information on the programme, including application requirements and materials, please visit www.expressionanalysis.com/grant.
EP News Bureau
- Advertisement -
